Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT capsules added to standard second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease
MOH_2021-08-23_010221Phase 2Not yet recruiting
- Sponsor
- ישראל הניג
- Start
- Aug 2021
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic fecal microbiota in Acute Graft-Versus-Host Disease (aGvHD), sponsored by ישראל הניג. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on MOH_2021-08-23_010221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-23_010221.